Dopamine disruption and autism phenotypes in slc6a3-/- zebrafish: Behavioural and molecular insights.

Scientists created genetically modified zebrafish that couldn't properly process dopamine, a brain chemical important for movement and emotions. These fish showed autism-like behaviors such as being less active, more anxious, and having trouble with social interactions. When treated with certain medications (risperidone and clozapine), the fish improved. This research helps us understand how dopamine problems might contribute to autism and provides a way to test new treatments.

This preclinical study used CRISPR-Cas9 gene editing to create zebrafish lacking the slc6a3 gene, which is crucial for dopamine transport. The knockout zebrafish showed significantly reduced dopamine levels and exhibited autism-like behaviors including decreased motor activity, increased anxiety, impaired social interactions, and repetitive 'digging' behavior. Pharmacological treatment with antipsychotic medications risperidone and clozapine improved these symptoms, with risperidone showing superior effects. Transcriptomic analysis revealed alterations in nervous system-related genes that may contribute to the observed behavioral abnormalities.

This research provides insights into dopamine's role in autism spectrum disorder and establishes a zebrafish model for studying autism mechanisms and testing potential treatments.

This research provides mechanistic insights into dopamine's role in autism and suggests antipsychotic medications may help with certain autism symptoms. However, being an animal model study, clinical translation requires careful consideration and human studies before informing treatment decisions.

This is a preclinical animal study using zebrafish, which may not fully translate to human autism. Sample sizes are not reported. The study design details and statistical methods are unclear from the abstract. Long-term effects of interventions were not assessed.

Dopamine plays a crucial role in regulating movement, motivation, attention, and emotions. Disruptions in dopamine metabolism have been linked to various psychiatric disorders, including autism spectrum disorder (ASD). In this study, we generated an slc6a3 knockout zebrafish model using the CRISPR-Cas9 system to investigate the relationship between dopamine dysfunction and autism. Our results revealed that slc6a3 knockout significantly reduced dopamine levels, leading to impaired dopamine synthesis, transport, and metabolism.

Behavioural analysis demonstrated that slc6a3-/- zebrafish exhibited decreased motor activity, increased anxiety-like behaviour, and autism-related symptoms, such as impaired social ability and "digging" behaviour. Pharmacological intervention with risperidone and clozapine improved motor function, social interaction, and anxiety levels, with risperidone showing superior effects. Transcriptomic analysis identified significant changes in several nervous system-related genes in slc6a3-/- zebrafish, suggesting that these gene alterations may contribute to the observed behavioural abnormalities. Our study highlights the crucial role of dopamine dysfunction in autism and establishes slc6a3-/- zebrafish as a valuable model for studying autism and screening potential therapeutic drugs.